Research programme: central nervous system disorder therapeutics - Sunovion PharmaceuticalsAlternative Names: CNS disorder therapeutics - Sunovion Pharmaceuticals
Latest Information Update: 14 Aug 2013
At a glance
- Originator Sunovion Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 13 Aug 2013 Early research in CNS disorders in USA (unspecified route)